



## Harnessing Intercellular Signals to Engineer the Soil Microbiome

Journal:	<i>Natural Product Reports</i>
Manuscript ID	NP-REV-05-2021-000034.R2
Article Type:	Review Article
Date Submitted by the Author:	17-Nov-2021
Complete List of Authors:	<p>Connolly, Jack; The University of Manchester, Manchester Institute of Biotechnology          Harcombe, William; University of Minnesota College of Biological Sciences          Smanski, Michael; University of Minnesota Twin Cities, Biochemistry, Molecular Biology and Biophysics; University of Minnesota Twin Cities, BioTechnology Institute          Kinkel, Linda; University of Minnesota Twin Cities, Department of Plant Pathology          Takano, Eriko; The University of Manchester, Manchester Institute of Biotechnology          Breitling, Rainer; The University of Manchester, Manchester Institute of Biotechnology</p>

## REVIEW

## Harnessing Intercellular Signals to Engineer the Soil Microbiome

Jack A. Connolly,<sup>a</sup> William R. Harcombe,<sup>b,c</sup> Michael J. Smanski,<sup>b,d</sup> Linda L. Kinkel,<sup>b,e</sup> Eriko Takano<sup>\*a</sup> and Rainer Breitling<sup>a</sup>

Received 00th January 20xx,  
Accepted 00th January 20xx

DOI: 10.1039/x0xx00000x

Covering: Focus on 2015 to 2020.

Plant and soil microbiomes consist of diverse communities of organisms from across kingdoms and can profoundly affect plant growth and health. Natural product-based intercellular signals govern important interactions between microbiome members that ultimately regulate their beneficial or harmful impacts on the plant. Exploiting these evolved signalling circuits to engineer microbiomes towards beneficial interactions with crops is an attractive goal. There are few reports thus far of engineering the intercellular signalling of microbiomes, but this article argues that it represents a tremendous opportunity for advancing the field of microbiome engineering. This could be achieved through the selection of synergistic consortia in combination with genetic engineering of signal pathways to realise an optimised microbiome.

1	<b>1</b>	<b>Introduction</b>	23	<b>6</b>	<b>Author contributions</b>
2	<b>1.1</b>	<b>Defining a signal</b>	24	<b>7</b>	<b>Conflicts of interest</b>
3	<b>2</b>	<b>Natural product signals in the soil microbiome</b>	25	<b>8</b>	<b>Acknowledgements</b>
4	<b>2.1</b>	<b>Quorum sensing and inhibition</b>	26	<b>9</b>	<b>References</b>
5	<b>2.2</b>	<b>Cross-kingdom signalling</b>			
6	<b>2.3</b>	<b>Regulation of natural product biosynthesis</b>			
7	<b>2.4</b>	<b><i>Streptomyces coelicolor</i> – a case study of soil microbial signalling</b>	27	<b>1</b>	<b>Introduction</b>
8			28		
9	<b>2.5</b>	<b>Uncovering signalling in uncultured bacteria</b>	29		
10	<b>3</b>	<b>Manipulation of soil microbiomes</b>	30		
11	<b>3.1</b>	<b>Chemical and enzyme additives to soil</b>	31		
12	<b>3.2</b>	<b>Genetic engineering of the microbiome <i>in situ</i></b>	32		
13	<b>3.3</b>	<b>Bio-inoculation of soil with beneficial bacteria</b>	33		
14	<b>4</b>	<b>Building an optimised consortium</b>	34		
15	<b>4.1</b>	<b>Selection of consortium members</b>	35		
16	<b>4.2</b>	<b>Modern technologies for the genetic engineering of soil bacteria</b>	36		
17			37		
18	<b>4.3</b>	<b>Identification and development of parts for signal engineering</b>	38		
19			39		
20	<b>4.4</b>	<b>Beneficial outcomes from the application of an optimised microbiome</b>	40		
21			41		
22	<b>5</b>	<b>Conclusions</b>	42		
			43		
			44		
			45		
			46		
			47		
			48		
			49		
			50		
			51		
			52		
			53		
			54		

\* Corresponding author

<sup>a</sup> Manchester Institute of Biotechnology, Manchester Synthetic Biology Research Centre SYNBIOCHEM, Faculty of Science and Engineering, School of Natural Sciences, Department of Chemistry, The University of Manchester, Manchester, M1 7DN, UK.

<sup>b</sup> BioTechnology Institute, University of Minnesota, Twin-Cities, Saint Paul, MN55108, USA.

<sup>c</sup> Department of Evolution, and Behaviour, University of Minnesota, Twin-Cities Saint Paul, MN55108, USA.

<sup>d</sup> Department of Biochemistry, Molecular Biology and Biophysics, University of Minnesota, Twin-Cities, Saint Paul, MN55108, USA.

<sup>e</sup> Department of Plant Pathology, University of Minnesota, Twin-Cities, Saint Paul, MN 55108, USA.

### 1 Introduction

Microbiomes engage in key interactions with associated multicellular eukaryotes, from influencing human gut health to interacting synergistically with fungus-farming ants<sup>1,2</sup>. The soil microbiome, the community of microorganisms (bacteria, fungi, protists and archaea) in the soil environment, is crucial to plant health and growth<sup>3</sup>. Modern DNA sequencing technologies have readily allowed for the identification of the constituents of the soil microbiome and the genes within those species, including those members that classically have been difficult to study as they have to date proved unculturable in the lab. Microbiome composition varies with external factors such as pH, temperature, water levels and agriculture methods; for instance, increases in the frequency of *Streptomyces* species were observed with longer crop rotation intervals<sup>4–8</sup>. Plants can also influence their associated microbiomes, including through root exudates such as jasmonic acid (1) or triterpenes<sup>9–13</sup>. Plant-mediated shifts in composition can occur rapidly during the lifecycle of the plant; for example, *Arabidopsis* in late growth stages enriches nitrogen-fixing bacteria<sup>14</sup>. The soil microbiome in agricultural fields commonly includes plant pathogens such as the bacterium *Pseudomonas syringae* or the fungus *Claviceps purpurea*<sup>15,16</sup>, but it can also provide disease suppression through ubiquitous genera such as *Bacillus*, *Pseudomonas* and *Streptomyces*<sup>17–21</sup>. Numerous plant growth promoting bacteria (PGPB) have been discovered<sup>22</sup>, that can improve growth of

55 crops such as rice<sup>23</sup>, including in the presence of soil  
56 contaminants such as copper<sup>24</sup>, through diverse mechanisms<sup>112</sup>  
57 Given the major impact of the soil microbiome on crops,<sup>113</sup>  
58 the development of enhanced soil microbiomes for agricultural<sup>114</sup>  
59 use is an attractive goal. While traditional approaches have<sup>115</sup>  
60 focused on crop rotation or the use of organic amendments<sup>116</sup>  
61 including green manures, more recent work has focused on  
62 bio-inoculation and host mediated-evolution<sup>25–30</sup>. To optimise  
63 a microbiome for its associated plant, it is necessary to add or  
64 facilitate organisms that carry genes that encode plant<sup>117</sup>  
65 beneficial functions. However, such a strategy has obvious<sup>118</sup>  
66 limitations: for example, in the bacterial genus *Streptomyces*<sup>119</sup>  
67 which is particularly important for plant health, secondary<sup>120</sup>  
68 metabolite biosynthetic gene clusters are often silent, i.e. not  
69 expressed under laboratory conditions<sup>31–34</sup>. In a case like this,<sup>121</sup>  
70 it is not sufficient for the beneficial genes to be present in the  
71 microbiome gene pool, but they also have to be expressed<sup>122</sup>  
72 That is to say, the correct signal or stimulus needs to be  
73 present to unlock their beneficial phenotype. This can be most  
74 directly achieved by manipulation of microbiome intercellular  
75 signalling; this goal, therefore, represents an exciting and  
76 relatively unexplored avenue towards the enhancement of soil  
77 microbiomes<sup>35</sup>. However, to realise this goal and effectively  
78 reverse-engineer the microbiome, we first need to consider  
79 our current knowledge of signalling within microbiomes.

### 80 1.1 Defining a signal

81 In the broad sense, a molecule produced by an organism that  
82 elicits a reaction in another organism is considered a *signal*.<sup>123</sup>  
83 However, this usage has often been considered too unspecific,<sup>124</sup>  
84 and alternative definitions have been variously proposed. For  
85 example, according to the more narrow criteria of Diggle and  
86 colleagues<sup>36</sup>, which we apply here, only molecules involved in  
87 a system that has evolved due to a fitness benefit to both  
88 sender and receiver are considered as *signals* in the strict  
89 sense. In contrast, where an excreted molecule does not  
90 impart a fitness benefit to the sender, but only to the receiver,  
91 it is considered a *cue*. Systems that have evolved so that the  
92 secreted molecule induces a response in a receiver without  
93 associated fitness benefit are considered *coercive*.

94 Winzer, Hardie & Williams propose alternative criteria<sup>125</sup>  
95 which rely on functional rather than evolutionary<sup>126</sup>  
96 characteristics, to define when a natural product should be  
97 considered a cell-to-cell signal molecule<sup>37</sup>. Production of the  
98 signal must occur at specific growth stages or environmental  
99 conditions. It must accumulate extracellularly, be recognised  
100 by a specific receptor, and generate a concerted response at a  
101 threshold concentration. The response must extend beyond  
102 metabolism or detoxification of the signal.

103 A case where the different definitions of signals become  
104 relevant are sub-inhibitory concentrations of antibiotics (SICA).<sup>127</sup>  
105 According to the functional criteria of Winzer and colleagues,<sup>128</sup>  
106 SICA could be considered signals<sup>38</sup>, as they can elicit responses  
107 beyond resistance, such as altering nutrient use in the receiver  
108 cell<sup>39</sup>. However, communication via SICA effecting changes in  
109 nutrient use are not likely to confer a fitness benefit to the  
110 sender; thus, according to the evolutionary definition of Diggle

and colleagues, SICA would be considered cues, rather than  
signals. But in an alternative scenario, where sensing of an  
antibiotic promotes co-operative biofilm formation, it confers  
a fitness benefit to the sender as well and can be considered a  
signal in the strict sense. Thus, dependent on the response  
elicited, antibiotics can be cues or signals by this definition<sup>40</sup>.

## 2 Natural product signals in the soil microbiome

Soil microbiome constituents use a variety of intercellular  
signals (1-11; Figure 1) and cues to regulate natural product  
(12-23; Figure 2) biosynthesis, and to mediate interactions  
with the surrounding plants and other microbial species. These  
range from PGPB-produced auxins to antibiotics at sub-  
inhibitory concentrations. Understanding of the enzymatic  
pathways responsible for signal transmission, reception and  
response is an essential prerequisite to their use in  
engineering a signal-optimised microbiome towards plant  
health.

### 2.1 Quorum sensing and inhibition

A well-studied example of intercellular microbiome signalling is  
quorum sensing (QS) in diverse bacterial populations. Signalling  
interactions among *Pseudomonas*, are of particular  
interest as this genus includes both PGPBs and notorious plant  
pathogens (e.g., *P. syringae*), as well as a number of  
opportunistic pathogens (including the human pathogen *P.*  
*aeruginosa*). All of these use acyl-homoserine lactone (AHL) QS  
to regulate virulence factors such as pyocyanin (12)<sup>41,42</sup>.  
Canonically, QS includes a LuxI-type AHL synthase and LuxR  
transcriptional regulator that detects the signal; however,  
organisms containing only LuxR also exist (without a  
corresponding LuxI AHL synthase) that can sense other signals  
such as photopyrones (2)<sup>43</sup>. As *Pseudomonas* species are  
influential to plant health, and QS perhaps the most studied  
class of signalling, QS is an auspicious choice for the genetic  
engineering of intercellular signalling.

Importantly, in nature, QS does not simply occur between  
members of one species, but rather can be influenced by other  
microbes and plants, via crosstalk and eavesdropping  
interactions. For instance, *Streptomyces* can produce quorum  
sensing inhibitory (QSI) compounds that interrupt *P.*  
*aeruginosa* QS regulation and pathogenesis<sup>44</sup>. Organisms can  
also produce enzymes that degrade quorum sensing signals (of  
their own or other species), in a processes called quorum  
quenching (QQ)<sup>45</sup>. *Agrobacterium fabrum* (formerly known as  
*Agrobacterium tumefaciens*) produces QQ enzymes that  
degrade the bacteria's own QS AHL, as part of a regulatory  
system for conjugative transfer of the tumour-inducing  
plasmid<sup>46</sup>. In generating a signal-optimised microbiome, QSI  
and QQ could both be used to inhibit QS systems regulating  
plant pathogen virulence factors. Indeed, this would mimic an  
interaction that has evolved in some soil microbiomes in  
nature, where the PGPB *Pseudomonas segetis* P6 was  
observed to degrade a broad range of AHLs and consequently  
confer protection from pathogens such as *Pseudomonas*  
*syringae* pv tomato<sup>47</sup>.




Figure 1 – Examples of natural product signalling molecules in the soil

165 Whilst often associated with pathogenesis, bacterial QS can  
 166 also be directly beneficial to plants which can detect bacterial  
 167 AHLs<sup>48</sup>. In *Arabidopsis*, introduction of *N*-hexanoyl-  
 168 homoserine-lactone (3) induced changes in the transcriptome  
 169 and promoted root growth, whereas *N*-decanoyl-  
 170 homoserine-lactone decreased root growth<sup>49</sup>. Bacterial AHLs  
 171 can both promote and downregulate sporulation of moss in a  
 172 concentration-dependent manner<sup>50</sup>. Therefore, when  
 173 considering optimising QS to benefit the plant in the  
 174 microbiome, it is not simply a matter of inhibiting or quenching  
 175 all signals.

## 177 2.2 Cross-kingdom signalling

178 Plant eavesdropping on microbial QS is an example of cross-  
 179 kingdom signalling, which could have powerful effects when  
 180 engineered carefully. There are other known cases of cross-  
 181 kingdom interactions with important effects on plant health,  
 182 for instance, bacterial LuxR-type regulators have evolved to  
 183 sense plant exudates, such as OryR in the pathogen  
 184 *Xanthomonas oryzae* pv. *oryzae*, which can sense an  
 185 uncharacterised molecule secreted by rice plants, inducing  
 186 expression of genes related to motility and virulence<sup>51</sup>. Cross-  
 187 kingdom signalling has also been observed from the yeast  
 188 *Saccharomyces cerevisiae* to the bacterium *Streptomyces*  
 189 *venezuelae*, where trimethylamine induced unusual horizontal  
 190 hyphal growth, independent of the canonical *Streptomyces*  
 191 developmental regulators (*bld* and *whi*)<sup>52,53</sup>. These examples  
 192 demonstrate that microbiome signal engineering needs to be  
 193 considered within the context of the whole microbial

community and associated plants. It is conceivable that a  
 pairwise signalling interaction characterised between two  
 organisms in a laboratory setting could have unexpected  
 effects on other members of a diverse microbiome.

Cross-kingdom signalling can also be directed towards  
 insects; virtually all *Streptomyces* strains produce geosmin (4),  
 which attracts springtails<sup>54</sup>. Geosmin biosynthesis is under the  
 regulation of sporulation-specific transcription factors,  
 suggesting that it may have evolved to promote the spread of  
 spores in the soil via the insect. Such signals could be used to  
 modulate insect populations, as demonstrated by the  
 significant differences observed in aphid numbers per ragwort  
 plant when grown in soils preconditioned with different plants;  
 an effect postulated to be mediated by soil fungal  
 communities<sup>55</sup>. Soil microbiomes from different crop soils can  
 affect the behaviour of insects, decreasing larval feeding on  
*Arabidopsis thaliana*<sup>56</sup>. Signals could also be used to recruit  
 beneficial insects, as in the case of ladybugs being attracted by  
 synthetic 2-butanone (5)<sup>57</sup>. Synthetic biology allows us to  
 develop microbial *in vivo* biosynthetic pathways to produce  
 such signals, such as in *E. coli* engineered for 2-butanone  
 production<sup>58</sup>. Signalling to insects, whether to attract, repel or  
 modulate their behaviour, provides an important avenue  
 through which microbiome engineering could benefit crop  
 health.

Review

Natural Product Reports




Figure 2 - Natural Products discussed in this review

### 2.3 Regulation of natural product biosynthesis

Soil microbiomes can be disease-suppressive through activities such as the production of antibiotics by their constituent bacteria, which is typically regulated by intercellular signals. QS systems have evolved to regulate natural product biosynthesis, such as for mupirocin (**13**) production in *Pseudomonas fluorescens*. The biosynthetic gene cluster (BGC) for mupirocin includes *mupI*, encoding an N-Acyl homoserine lactone synthase; the addition of exogenous N-(3-Oxodecanoyl)-L-homoserine lactone (**6**) signal was observed to restore antibiotic production in a *mupI* knockout strain, demonstrating this natural product signal is required for mupirocin biosynthesis<sup>59</sup>. However, addition of the lactone to the WT producer did not increase titre, nor stimulate early antibiotic production, indicating the multi-level regulation of such natural product pathways<sup>60</sup>.

The prolific secondary metabolite-producing genus *Streptomyces* uses  $\gamma$ -butyrolactones (GBL) and  $\gamma$ -butenolides signals to regulate secondary metabolite production, such as regulation of streptomycin (**14**) biosynthesis by A-factor (**7**) in *Streptomyces griseus*<sup>61–64</sup>. Similarly, *Streptomyces coelicolor* butyrolactones (SCBs, **8**) act as a diffusible signal, able to relieve ScbR repression at promoters such as for *cpkO*, which encodes an activator for the coelimiricin (**15**) BGC<sup>65–67</sup>. In *Streptomyces avermitilis*, the cognate GBL avenolide (**9**) induces production of the insecticide avermectin (**16**). No increase in production of avermectin was observed with SCB1, however, providing evidence of the specificity of these signals<sup>62</sup>. As well as being of major interest in drug discovery, understanding and engineering this intercellular regulation to potentially switch on silent biosynthetic gene clusters encoding metabolites that benefit the plant should be considered as a promising strategy towards generating a signal-optimised microbiome<sup>35</sup>.

Where typically a single bacterial species will both produce and detect the signals regulating secondary metabolism, there is also evidence of cross-strain signalling. Genome analysis of *Streptomyces albidoflavus* J1074 revealed the presence of a predicted GBL receptor but no biosynthesis genes, and intriguingly heterologously introducing *S. coelicolor* GBLs induced paulomycin (**17**) biosynthesis<sup>68</sup>. This again highlights the need to consider multiple microbiome members when engineering signalling.

### 2.4 *Streptomyces coelicolor* – a case study of soil microbial signalling

As alluded to in the previous section, the regulation of natural product biosynthesis is not typically as simple as inducing production in response to a single signal. Rather, each signal provides one input into a complex regulatory network that is not always well understood. The model soil bacterium *S. coelicolor* provides an excellent exemplar given the importance of its genus for natural product biosynthesis and the extensive previous studies into its secondary metabolite regulatory networks.




Figure 3 - Interaction of signals with selected transcription factors regulating natural product biosynthesis in *S. coelicolor*. Black arrows represent activation and repression, blue arrows chemical reaction/biosynthesis<sup>71–73</sup>. See text for details.

The complexity of the network function is demonstrated by the observation that deletion of *scbA*, without which SCB signalling molecules are not biosynthesised, increases the production of actinorhodin (**18**) and undecylprodigiosin (**19**)<sup>65</sup>, which are not directly under SCB regulation. Later ChIP-seq, transcriptomic and proteomic studies revealed the network responsible for this phenotype (summarised in Figure 3), and the pleiotropic effects of these signals<sup>69–71</sup>: deletion of *scbA* abolishes biosynthesis of the SCB signals, which are therefore not available to bind to transcription factor ScbR. Transcription of *scbR* was observed to be diminished in the  $\Delta scbA$  mutant, as ScbR represses its own promoter<sup>65</sup>. ScbR represses production of another transcription factor CpkO, and therefore deletion of *scbA* should increase *cpkO* expression. CpkO activates expression of the pseudo-GBL receptor ScbR2, which activates transcription factors regulating actinorhodin, undecylprodigiosin and calcium-dependent antibiotic (CDA, **20**) biosynthesis. ScbR2 does not bind SCBs, but instead responds to antibiotic signals such as the endogenous actinorhodin and undecylprodigiosin, as well as jadomycin B (**10**) produced by *Streptomyces venezuelae*<sup>72</sup>. ScbR and ScbR2 interact with the regulation of glucose catabolism, for example repressing production of acetyl-CoA carboxylase AccA2, controlling the flux from acyl-CoA to malonyl-CoA precursor for these polyketide natural products<sup>70</sup>. The regulatory network is not limited to transcription factors; for example, the global regulator *blbA* encodes a tRNA<sup>LEU</sup> for the rare codon UUA, allowing for translational control of RedZ in undecylprodigiosin biosynthesis<sup>73</sup>.

These examples from *S. coelicolor* are far from exhaustive, but they indicate the complexity of the regulatory networks that signalling molecules perturb. Understanding of these networks and the wider indirect effects of signals is key to successfully engineering signalling within a microbiome. This also emphasises the importance of -omics techniques in studying these effects, as discussed in the following sections.

314 **2.5 Uncovering signalling in uncultured bacteria** 369  
315 GBL circuits in *Streptomyces* and QS in *Pseudomonas* species 370  
316 are well-studied signalling systems, where many signalling 371  
317 molecules and cues have been characterised, together with 372  
318 the molecular mechanisms cells use to respond to them. The 373  
319 many studies that have contributed to this knowledge have 374  
320 often relied on the culturability of the signalling partners in the 375  
321 lab. However, it is estimated as little as <1% of bacteria are 376  
322 culturable under standard laboratory conditions, limiting the 377  
323 possibilities for characterising signalling in this manner. 378  
324 Furthermore, under laboratory conditions, microbes might not 379  
325 produce and respond to signals as they would in a natural soil 380  
326 ecosystem. The experimental parameters are complex, 381  
327 studying a given signalling pathway in the laboratory may 382  
328 require certain media, temperature, pH or combinations of 383  
329 organisms. It may be difficult to identify a metabolically 384  
330 inactive signaller or responder from a natural system, but this 385  
331 is essential before being able to reproduce the signalling in the 386  
332 lab. This means that potentially most bacterial signals and their 387  
333 effects are yet to be investigated. Expanding our 388  
334 understanding of these signals is important to achieving the 389  
335 goal of a signal-optimised microbiome that benefits crops. 390  
336 One way of overcoming the culturability barrier is to 391  
337 develop technology to dramatically increase the range of 392  
338 culturable bacteria, such as the isolation chip (iChip) 393  
339 technology, which facilitated discovery of a promising new 394  
340 antibiotic, teixobactin (**21**), from a previously inaccessible 395  
341 microbe<sup>75,76</sup>. Despite these efforts, a large proportion of the 396  
342 microbiome likely remains uncultured for the foreseeable 397  
343 future. An alternative route of access is provided by *in situ* 398  
344 methodologies. Metagenomic analyses can reveal the genetic 399  
345 pool of uncultured microbial communities, and potential 400  
346 signalling interactions can be predicted through genetic 401  
347 homology to known systems. However, this intrinsically limits 402  
348 the novelty of discoveries. Metatranscriptomics have been 403  
349 used to gain insight into the gene expression of the 404  
350 microbiome in response to environmental stimuli such as soil 405  
351 contamination and global warming<sup>77-79</sup>. It also allows for the 406  
352 investigation of the gene expression patterns underlying signal 407  
353 biosynthesis, as demonstrated in phytoplankton-associated 408  
354 bacteria with indole-3-acetic acid (**11**) signalling<sup>80</sup>, and could 409  
355 be used to monitor the wider effect of introducing a signal- 410  
356 optimised consortium. 411

357 **2.6 Studying the effects of signals** 412  
358 Indeed, in general, an alternative to investigating the signals 413  
359 themselves is to probe cells responses instead, looking for 414  
360 changes in transcription, metabolism, or phenotype in 415  
361 response to potential signals. Introduction of reporter genes 416  
362 into two silent gene clusters for burkholdac A (**22**) and 417  
363 malleilactone A (**23**) in *Burkholderia thailandensis* allowed for 418  
364 the high-throughput identification of elicitors, potential 419  
365 signalling molecules, from a library of 640 compounds, a 420  
366 exciting proof of concept<sup>81</sup>. This information could be used 421  
367 together with genetic engineering of the biosynthesis of these 422  
368 elicitors, to develop orthogonal signalling circuits that

maintain and regulate novel microbiome components independently of the native soil microbiome.

With the maturity of RNA-seq, transcriptomics can yield insight into genome-wide expression effects of a signal. For example, this approach has been used to elucidate the *Pseudomonas syringae* transcriptome response to the plant immune system<sup>82</sup>. Concurrent use of multiple molecular profiling technologies represents a promising avenue to comprehensively characterise signalling in a microbiome; to effectively bring these complex datasets together to predict the emergent properties of a signalling network from genome to transcriptome to metabolome and phenotype will require the development of computational models<sup>83</sup>. Models have been developed for understanding signalling circuits, such as  $\gamma$ -butyrolactone signalling in *S. coelicolor*<sup>66</sup>, or to predict the metabolic interactions within an entire multi-species community, as demonstrated with the experimentally-validated prediction of the equilibrium of a three-species consortium with COMETS<sup>84</sup>. As we expand our understanding of signalling in the soil by diverse complementary methodologies, we increase our possibilities for its reverse-engineering. We are better able to predict how our perturbations will affect other organisms in the microbiome and therefore how to design signalling circuits in the context of a microbial consortium to benefit plants.

### 3 Manipulation of soil microbiomes

It is important to consider the avenues available for achieving a signal-optimised microbiome with tangible benefits to crops in practice. Options include use of soil additives, mobile genetic elements or bio-inoculation of an optimised consortium, each with their advantages and disadvantages, and with the possibility of concurrent use.

#### 3.1 Chemical and enzyme additives to soil

The composition of the crop microbiome is heavily influenced by agricultural practices<sup>85</sup>, including the use of fertilisers, pesticides, and organic amendments, which affect the microbiome in a soil-specific manner<sup>86</sup>. For instance, addition of biochar to Chinese ginseng soil enriched populations of *Bacillus*<sup>87</sup>, whereas in rice soils <sup>13</sup>C-labelled biochar was associated with preferential metabolism by Gram negative species, compared with addition of straw and rice root<sup>88</sup>. Carbon amendment through the addition of compounds such as fructose and glucose was observed to alter bacterial community composition and enrich *Streptomyces* antagonistic phenotypes<sup>89,90</sup>. These factors are important when considering the practical application of an optimised microbiome to crop soils; it might be that certain fertilisation treatments and agricultural practices promote the perseverance of beneficial consortia.

The direct addition of enzymes to soil could also be considered for degrading signals. Lactonase enzymes that specifically degrade AHLs have been introduced to a bioreactor within silica capsules, resulting in decreased *Pseudomonas* biofilm formation<sup>91</sup>. However, it would be challenging to

423 achieve this on a large scale, to protect the enzymes in the soil  
 424 environment and to deliver them precisely to the local  
 425 required for function. Furthermore, the general degradation  
 426 AHLs is not desirable, as these can regulate plant-beneficial  
 427 effects and AHLs would have a significant role in intercellular  
 428 signalling in our model microbiome. However, the concept of  
 429 adding enzymes that affect soil signalling in a contemporary  
 430 manner could be used to control signalling and therefore  
 431 phenotypes. For example, a lactonase could be added that  
 432 degrades a specific AHL, the absence of which has been  
 433 designed to promote phosphate solubilising gene pathways  
 434 within the designed rhizosphere. This could allow *in situ*  
 435 control of the phenotype, for instance allowing us to increase  
 436 phosphate solubilisation by desirable bacteria<sup>92</sup>. The direct  
 437 addition of the enzymes to soil would likely be short-lived and  
 438 may prove impractical; an alternative approach could be to  
 439 inoculate with a microbe that produces and secretes the  
 440 enzyme instead. These proposed exogenous control systems  
 441 could supplement a genetically-engineered microbiome  
 442 towards plant benefit.

### 443 3.2 Genetic engineering of the microbiome *in situ*

444 The genetic engineering of the microbiome *in situ* has so far  
 445 been of particular interest in the study of animal-associated  
 446 microbiomes<sup>93</sup>. It is achieved through the introduction of  
 447 mobile genetic elements: plasmids and bacteriophages. In the  
 448 mouse gut, conjugative plasmids in combination with the  
 449 Himar transposon were successful in transmitting test reporter  
 450 genes (GFP and carbenicillin resistance) through the  
 451 microbiome<sup>94</sup>. A prudent choice of plasmid for  
 452 microbiomes could be the broad-host range RP4, which is  
 453 transmissible to both Gram positive and negative strains  
 454 also encodes a toxin–antitoxin-based addiction system and  
 455 DNA partition mechanisms to prevent plasmid loss. Inoculation  
 456 of vegetable field soil with *Pseudomonas putida* carrying  
 457 RP4-derivative demonstrated the ability of the plasmid to  
 458 transfer to the existing soil microbiome and persist over a  
 459 day period<sup>95</sup>. However, such approaches do not allow for fine  
 460 control; it is impossible to predict which bacteria would  
 461 receive the plasmid, and there is potential for non-target  
 462 effects. Indeed, in a natural cautionary tale, adhesion systems  
 463 aiding plant growth promotion in *Pseudomonas* may have  
 464 undergone horizontal gene transfer to *Erwinia carotovora*  
 465 within which they contribute to plant virulence<sup>96</sup>. An  
 466 advantage of engineering *in situ* is that the existing  
 467 microbiome has already evolved for its niche and can  
 468 therefore be expected to persist. However, given the inherent  
 469 lack of control and the significant ethical and regulatory  
 470 boundaries to *in situ* genetic engineering, bio-inoculation with  
 471 engineered consortia is a more attractive option in soil.

### 472 3.3 Bio-inoculation of soil with beneficial bacteria

473 The use of bacterial and/or fungal bio-inoculants to benefit  
 474 plants is well-established, with diverse studies demonstrating  
 475 plant growth promotion and pathogen antagonism<sup>97–101</sup>. In  
 476 theory, the inoculation of crop soil with PGPB or disease  
 477 suppressive bacteria can provide an immediate means to

benefit agriculture. In a simplistic example, one could identify  
 a new *Streptomyces* strain that in lab cultures produces an  
 antibiotic effective against plant pathogens and expect  
 inoculation of crop soil to provide pathogen suppression.  
 However, the inoculant must invade and persist in the natural  
 microbiome<sup>102</sup>, as has been demonstrated in the mammalian  
 gut with the colonisation of genetically engineered  
 strains<sup>103,104</sup>, and it must produce or receive the relevant  
 intercellular signals to direct the production of the antibiotic.  
 Indeed, even in greenhouse experiments, persistence can be a  
 problem; e.g., the population of two PGPB strains was  
 observed to drop by 95% and 99% between 2 and 5 days post  
 inoculation<sup>105</sup>. A potential solution to this is to deliver the  
 inoculum by a different means. In Chinese kale soil,  
 colonisation and plant growth promotion of *Ensifer fredii* was  
 achieved when immobilised in agar, where liquid culture  
 inocula failed<sup>106</sup>. However, a solution to persistence issues  
 might be to apply a consortium that acts synergistically, which  
 also furthers the possible beneficial phenotypes mediated by  
 signalling that can be realised. In an example of co-operation,  
 co-inoculation of *Paenibacillus mucilaginosus* and  
*Sinorhizobium meliloti* mediated greater growth promotion of  
 alfalfa than either inoculant individually<sup>107</sup>. The survival of  
 introduced *Pseudomonas* communities increased with  
 increased microbial diversity of the inoculum, also  
 corresponding with pathogen suppression<sup>108</sup>. In the field,  
 inoculation of degraded arable land with nearby biodiverse  
 heathland and grassland soil effects a profound increase in  
 plant species coverage over a period of six years<sup>109</sup>. This  
 demonstrates that there is good scope for the application of  
 an engineered microbiome to a real-world field to deliver  
 lasting benefits. Indeed the engineering of microbiomes was  
 the focus of the most recent Engineering Biology Research  
 Consortium roadmap, that establishes the diverse anticipated  
 outcomes over the next 20 years, from engineering spatial  
 properties to distributing the burden of compound  
 biosynthesis<sup>110</sup>.

## 4 Building an optimised consortium

### 4.1 Selection of consortium members

A key step in curating a signal-optimised microbiome is  
 choosing its constituents<sup>35</sup>. Optimisation of signalling need not  
 be restricted to genetic engineering approaches; combinations  
 of strains that natively exchange signals that support plant-  
 beneficial phenotypes could underpin the selection of  
 microbiome constituents. One should also consider that  
 bacteria can promote the growth of other strains; for example,  
 the presence of *Streptomyces pactum* increases the population  
 of PGPB *Pseudomonas koreensis* GS in the rhizosphere<sup>111</sup>.  
 Microbiome constituent selection is key: in nature, members  
 of the microbiome have evolved in complex communities,  
 undergoing diverse species interactions within and across  
 kingdoms. The effects of cross-kingdom species interactions on  
 functional capacities is evidenced by significantly greater  
 inhibition between sympatric, co-evolved *Fusarium* and  
*Streptomyces* populations than allopatrically evolved strains<sup>112</sup>.



533 When a 185-member synthetic bacterial community was  
 534 applied to *Arabidopsis* seedlings, interference with auxin  
 535 signalling mediated by the auxin-degradation operon  
 536 conserved within the genus *Variovorax* was observed as being  
 537 key for normal root development<sup>113</sup>. Typing of 16S rRNA has  
 538 been used in studies to determine the core bacterial taxa  
 539 present in geographically distinct replicates of crop-associated  
 540 rhizospheres<sup>114–116</sup>. While the number of core taxa reported  
 541 in these experiments varies, they support the idea that there are  
 542 core phyla, such as Proteobacteria, almost ubiquitous and  
 543 present across soils. This suggests a substantial level of  
 544 robustness and persistence in these taxa, and it may be  
 545 sensible to develop candidate strains for engineering from  
 546 within this stable core.

548 **4.2 Modern technologies for the genetic engineering of soil**  
 549 **bacteria**

550 The real potential power of signalling can be unlocked through

the engineering of the genes and pathways encoding and  
 responding to these signals. We have more capability to  
 genetically engineer diverse bacteria than ever before,  
 particularly with the maturation of CRISPR methodologies for  
 bacterial genome engineering. In the prolific antibiotic-  
 producing genus *Streptomyces*, for example, CRISPR-Cas9  
 plasmids are available for precise genetic engineering  
 mediated by specific DNA double strand breaks, alongside  
 multiplex CRISPRi and base editing vectors<sup>117–119</sup>. Whilst there  
 is no guarantee that these work in all *Streptomyces* strains,  
 CRISPR-Cas9 plasmids are available with differing constitutive  
 and inducible regulation of *cas9*, which allows for tuning to  
 mediate any Cas9 toxicity issues<sup>120–123</sup>. These systems have  
 supplemented existing engineering options, such as phage  
 serine integrase mediated insertions, suicide plasmid-based  
 homologous recombination and replicative plasmid gene  
 expression<sup>124</sup>. There is a plethora of molecular biology cloning  
 methods for the efficient construction of these mutagenesis  
 plasmids from Golden Gate to Gibson Assembly<sup>125,126</sup>.




Figure 4 – Examples of potential benefits of a signal-optimized microbiome in agricultural applications<sup>35</sup>. 1) Intercellular signalling by genetically engineered microbes modulates and stabilises the population structure of a microbiome, including native and inoculated species, to regulate plant-beneficial outcomes. 2) Detection of plant pathogens in the soil by engineered microbes activates signal-specific disease suppression, with effective antimicrobials produced to inhibit growth. Intercellular lactone signalling regulating virulence factors is sensed by engineered surveillance bacteria and inhibited by quenching enzymes. 3) Engineered microbes produce volatile compounds that attract plant-beneficial insects, repel pests and dissuade feeding. 4) Engineered microbes undergo chemotaxis towards crop root exudates, aiding persistence of the engineered strains. Multiple mechanisms of plant growth promotion are activated upon root exudate detection, such as growth hormone secretion, phosphate solubilisation and nitrogen fixation.

570 Molecular biologists are no longer limited to sourcing 625  
 571 organism to amplify a genetic part of interest by PCR. 626  
 572 libraries are available, including, e.g., the BioBricks repository 627  
 573 maintained by iGEM that includes many studied signalling 628  
 574 systems<sup>127</sup>. In addition, the *de novo* synthesis of DNA by 629  
 575 variety of biotechnology companies is quickly becoming more 630  
 576 accessible and affordable. This allows unprecedented access 631  
 577 sequence space, which, when combined with our bacterial 632  
 578 genetic editing capabilities, allows real freedom in signal 633  
 579 engineering. 634

#### 580 4.3 Identification and development of parts for signal engineering 635

581 The possibilities for signal engineering are not limited to genes 636  
 582 as they naturally occur, as elegantly demonstrated in *E. coli* 637  
 583 a study involving the inner membrane sensor PhoQ and the 638  
 584 regulator it phosphorylates, PhoP<sup>128</sup>. Random mutagenesis 639  
 585 was performed of amino acids in the interface of both 640  
 586 proteins, and the resulting library screened at high throughput 641  
 587 for response to Mg<sup>2+</sup> levels using a *yfp* reporter gene assay 642  
 588 with flow cytometry. The former strategy allowed for the 643  
 589 generation of 58 insulated pathways, without crosstalk with 644  
 590 other PhoQ/PhoP pathway variants, effectively expanding the 645  
 591 possibilities for differentially engineering the regulatory 646  
 592 circuits of many genes at once. This can also be achieved 647  
 593 through the use of natural systems that do not crosstalk, for 648  
 594 example with the concurrent use of AHL and GBL signalling<sup>129</sup>. 649  
 595 Natural enzymes can be altered through structure-informed 650  
 596 rational engineering and directed evolution, as demonstrated 651  
 597 for lactonases with altered substrate specificity<sup>130</sup> and 652  
 598 increased quorum quenching activity<sup>131,132</sup>. These advances 653  
 599 allow us to develop enzymes to perform functions for which 654  
 600 naturally occurring enzymes are not available. This could allow 655  
 601 us to develop multiple concurrent signalling pathways that 656  
 602 interact in defined ways, whilst also expanding the possibilities 657  
 603 for effector genes that respond to such pathways; for example, 658  
 604 synthetic biology could provide the new biosynthesis route *in* 659  
 605 *vivo* to important plant hormones. 660

#### 606 4.4 Beneficial outcomes from the application of an optimised 661 607 microbiome 662

608 There are a variety of studies that demonstrate the diverse 663  
 609 outcomes achievable through engineering signalling. Social 664  
 610 interactions within a bacterial community have been artificially 665  
 611 generated, using the antimicrobial nisin as an intercellular 666  
 612 signal<sup>133</sup>. These included enforced cooperation, where the two 667  
 613 bacterial strains co-operatively biosynthesise nisin, which 668  
 614 subsequently induces tetracycline resistance in both partners 669  
 615 to allow survival under selection<sup>134</sup>. The possibilities for 670  
 616 engineering soil microbiomes are not limited to inter-bacterial 671  
 617 signalling: trans-kingdom signal genetic engineering has been 672  
 618 achieved, with the expression of a heterologous biosynthetic 673  
 619 pathway to the signalling molecule *scyllo*-inosamine in 674  
 620 plants<sup>135</sup>. The signals produced by these transgenic plants 675  
 621 were detected by rhizobial bacteria carrying the rhizopine 676  
 622 biosensor. This represents an important foundational advance 677  
 623 towards the use of synthetic biology to engineer plant 678  
 624 microbiome signalling pathways at the molecular level. 679

Engineering to suppress a pathogen has been demonstrated in  
*E. coli*, which was successfully engineered to both produce an  
antibiotic and self-lyse in response to a *Pseudomonas*  
*aeruginosa* AHL<sup>136</sup>. Indeed, disease suppression could be a  
relatively straightforward application of signal engineering,  
whether through interruption of virulence factor QS or the  
induction of microbial antibiotic production. Alternatively,  
bacteria can be engineered directly for plant growth  
promotion, via mechanisms such as nitrogen fixation. In the  
corn root isolate *Kosakonia sacchari*, the regulatory network  
for the nitrogen fixation operon (*nif*) has been engineered to  
optimise nitrogen fixation in corn<sup>137</sup>. This has also been  
demonstrated with the introduction of the *nif* pathway for  
nitrogen fixation to two cereal endophytes as well as  
*Pseudomonas protegens* Pf-5<sup>138</sup>, initially under IPTG inducible  
regulation. This demonstrates how synthetic biology allows us  
to introduce pathways that encode plant beneficial functions  
to heterologous bacteria. Furthermore, using a salicylic acid  
sensor to drive the *nif* pathway yielded a 1000-fold induction  
of nitrogenase activity. Salicylic acid and other root exudates  
could be used as signals to denote proximity to the crop, and  
selectively activate relevant genetic pathways in the  
bacterium. There is also the potential to regulate the relative  
populations of bacteria within the microbiome by artificial  
signalling; multiple QS systems introduced in tandem in *E. coli*  
have been used to regulate cell growth and populations in  
laboratory co-culture<sup>139</sup>. *E. coli* has also been engineered to  
sense and undergo chemotaxis towards hydrogen peroxide<sup>140</sup>.  
The same ideas could be applied to an engineered microbe in a  
crop soil microbiome, for instance to promote chemotaxis  
towards the crop root exudates, which could also help increase  
the persistence of the introduced bacteria.

## 5 Conclusions

To build an optimised microbiome, combinations of members  
would need to be selected and developed for persistence in  
field conditions and the robust exchange of signals to maintain  
the expression of functions critical to plant health and growth.  
This could be supported by genetic engineering of signal  
biosynthesis, degradation, and response circuits in some or all  
members of the engineered community, or within/by the plant  
host. Modern synthetic biology techniques provide the means  
to develop and install the parts needed for such systems. This  
engineered microbiome could inhibit pathogenic intercellular  
signals or sense them and specifically respond to provide  
antagonism. Bacteria could be engineered to undergo  
chemotaxis towards plant root exudates, followed by  
activation of plant growth promoting functions. The potential  
benefits of the application of such a signal-optimised  
microbiome are summarised in Figure 4.

This signal-optimised microbiome would be highly  
synergistic with plant host-mediated selection approaches,  
based on the evolution of enhanced microbiomes in response  
to artificial selective pressure towards a trait of interest<sup>141–143</sup>.  
Selection of the starting microbiome for such experiments is  
essential to their success<sup>27,144,145</sup>, and a signal-optimised

680 microbiome would prove an excellent starting point. Microbiomes  
 681 have the potential for mitigating the negative environmental  
 682 impacts of agriculture, enhancing plant productivity, increasing  
 683 plant resilience to environmental stress and reducing reliance  
 684 on external fertiliser and pesticide inputs. Engineered  
 685 microbiomes that capitalise on a deep understanding of the  
 686 complex interactions within soil and plant microbiomes are  
 687 needed to optimise the functional capacity of microbiomes to  
 688 support crop and ecosystem productivity.

689 **6 Author contributions**

690 JAC, ET and RB conceptualised the article. ET, RB, WRH, MJS &  
 691 LLK secured funding as part of the NSF/UKRI Signals in the Soil  
 692 program. JAC, ET and RB created the original draft, all authors  
 693 reviewed, contributed to and edited the manuscript.

694 **7 Conflicts of interest**

695 LLK is Chief Science Officer of Jord BioScience, and WRH and  
 696 MJS serve on the Jord BioScience Scientific Advisory Board.  
 697 Jord BioScience creates signal-optimised microbial consortia  
 698 for use in agriculture. This interest has been reviewed and  
 699 managed by the University of Minnesota in accordance with its  
 700 conflict of interest policies.

701 **8 Acknowledgements**

702 This review was supported through the Signals in the Soil  
 703 program: JAC, ET, and RB were funded via UK Research and  
 704 Innovation (UKRI; NE/T010959/1), and WH, MS, and LLK by  
 705 NSF (1935458).

706 **9 References**

707 1 O. Manor, C. L. Dai, S. A. Kornilov, B. Smith, N. D. Price, J. C.  
 708 Lovejoy, S. M. Gibbons and A. T. Magis, *Nat Commun*, 2020, **11**,  
 709 5206.  
 710 2 J. Barke, R. F. Seipke, S. Grünschow, D. Heavens, N. Drou, M. J.  
 711 Bibb, R. J. M. Goss, D. W. Yu and M. I. Hutchings, *BMC Biol*,  
 712 2010, **8**, 109.  
 713 3 V. Cordovez, F. Dini-Andreote, V. J. Carrión and J. M.  
 714 Raaijmakers, *Annu. Rev. Microbiol.*, 2019, **73**, 69–88.  
 715 4 M. Bahram, F. Hildebrand, S. K. Forslund, J. L. Anderson, N. A.  
 716 Soudzilovskaia, P. M. Bodegom, J. Bengtsson-Palme, S. Anslan,  
 717 P. Coelho, H. Harend, J. Huerta-Cepas, M. H. Medema, M. R.  
 718 Maltz, S. Mundra, P. A. Olsson, M. Pent, S. Pölme, S. Sunagawa,  
 719 M. Ryberg, L. Tedersoo and P. Bork, *Nature*, 2018, **560**, 233–  
 720 237.  
 721 5 P. V. Jauri, N. Altier, C. A. Pérez and L. Kinkel, *Phytobiomes*  
 722 *Journal*, 2017, **2**, 14–23.  
 723 6 E. Collier, A. Cestaro, R. Zanzotti, D. Bertoldi, M. Pindo, S. Larger,  
 724 D. Albanese, E. Mescalchin and C. Donati, *Microbiome*, 2019, **7**,  
 725 140.  
 726 7 K. Hartman, M. G. A. van der Heijden, R. A. Wittwer, S. Banerjee,  
 727 J.-C. Walser and K. Schlaeppli, *Microbiome*, 2018, **6**, 1–14.  
 728 8 J. Cordero, J. R. de Freitas and J. J. Germida, *Canadian Journal of*  
 729 *Microbiology*, 2019, **66**, 71–85.

9 H. Liu, L. C. Carvalhais, P. M. Schenk and P. G. Dennis, *Scientific*  
*Reports*, 2017, **7**, 1–8.  
 10 J. M. Chaparro, D. V. Badri and J. M. Vivanco, *The ISME Journal*,  
 2014, **8**, 790–803.  
 11 C. R. Fitzpatrick, J. Copeland, P. W. Wang, D. S. Guttman, P. M.  
 Kotanen and M. T. J. Johnson, *PNAS*, 2018, **115**, 1157–1165.  
 12 S. Gorka, M. Dietrich, W. Mayerhofer, R. Gabriel, J.  
 Wiesenbauer, V. Martin, Q. Zheng, B. Imai, J. Prommer, M.  
 Weidinger, P. Schweiger, S. A. Eichorst, M. Wagner, A. Richter,  
 A. Schintlmeister, D. Woebken and C. Kaiser, *Front Microbiol*,  
 2019, **10**, 168.  
 13 A. C. Huang, T. Jiang, Y.-X. Liu, Y.-C. Bai, J. Reed, B. Qu, A.  
 Goossens, H.-W. Nützmann, Y. Bai and A. Osbourn, *Science*,  
 2019, **364**, aau6389.  
 14 J. Yuan, J. M. Chaparro, D. K. Manter, R. Zhang, J. M. Vivanco  
 and Q. Shen, *Soil Biology and Biochemistry*, 2015, **89**, 206–209.  
 15 P. Tudzynski and J. Scheffer, *Molecular Plant Pathology*, 2004, **5**,  
 377–388.  
 16 X.-F. Xin, B. Kvitko and S. Y. He, *Nat Rev Microbiol*, 2018, **16**,  
 316–328.  
 17 O. Lastochkina, A. Baymiev, A. Shayahmetova, D. Garshina, I.  
 Koryakov, I. Shpirnaya, L. Pusenkova, I. Mardanshin, C. Kasnak  
 and R. Palamutoglu, *Plants*, 2020, **9**, 76.  
 18 J. Huang, Y. Pang, F. Zhang, Q. Huang, M. Zhang, S. Tang, H. Fu  
 and P. Li, *Eur J Plant Pathol*, 2019, **154**, 585–596.  
 19 S. W. Hong, D.-R. Kim, Y. S. Kwon and Y.-S. Kwak, *FEMS*  
*Microbiol Lett*, 2019, **366**, frz133.  
 20 M. de Boer, P. Bom, F. Kindt, J. J. B. Keurentjes, I. van der Sluis,  
 L. C. van Loon and P. A. H. M. Bakker, *Phytopathology*®, 2003,  
**93**, 626–632.  
 21 H. B. Slama, H. Cherif-Silini, A. Chenari Bouket, M. Qader, A.  
 Silini, B. Yahiaoui, F. N. Alenezi, L. Luptakova, M. A. Triki, A.  
 Vallat, T. Oszako, M. E. Rateb and L. Belbahri, *Front Microbiol*,  
 2018, **9**, 3236.  
 22 P. Martínez-Hidalgo, M. Maymon, F. Pule-Meulenberg and A. M.  
 Hirsch, *Can. J. Microbiol.*, 2018, **65**, 91–104.  
 23 Z. R. Suárez-Moreno, D. M. Vinchira-Villarraga, D. I. Vergara-  
 Morales, L. Castellanos, F. A. Ramos, C. Guarnaccia, G. Degrassi,  
 V. Venturi and N. Moreno-Sarmiento, *Front Microbiol*, 2019, **10**,  
 290.  
 24 X.-M. Ren, S.-J. Guo, W. Tian, Y. Chen, H. Han, E. Chen, B.-L. Li,  
 Y.-Y. Li and Z.-J. Chen, *Front Microbiol*, 2019, **10**, 1455.  
 25 F. T. de Vries, R. I. Griffiths, C. G. Knight, O. Nicolitch and A.  
 Williams, *Science*, 2020, **368**, 270–274.  
 26 U. G. Mueller and J. L. Sachs, *Trends in Microbiology*, 2015, **23**,  
 606–617.  
 27 M. C. Rillig, A. Tsang and J. Roy, *Front. Microbiol.*, 2016, **7**, 1967.  
 28 A. Sarwar, Z. Latif, S. Zhang, J. Zhu, D. L. Zechel and A.  
 Bechthold, *Front. Microbiol.*, 2018, **9**, 1126.  
 29 D. McNeely, R. M. Chanyi, J. S. Dooley, J. E. Moore and S. F.  
 Koval, *Can. J. Microbiol.*, 2017, **63**, 350–358.  
 30 J. Ke, B. Wang and Y. Yoshikuni, *Trends in Biotechnology*, 2020,  
**39**, 244–261.  
 31 S. C. Heinsch, S. Y. Hsu, L. Otto-Hanson, L. Kinkel and M. J.  
 Smanski, *BMC Genomics*, 2019, **20**, 13–16.  
 32 E. Kalkreuter, G. Pan, A. J. Cepeda and B. Shen, *Trends in*  
*Pharmacological Sciences*, 2020, **41**, 13–26.  
 33 P. J. Rutledge and G. L. Challis, *Nature Reviews Microbiology*,  
 2015, **13**, 509–523.  
 34 P. Vaz Jauri and L. L. Kinkel, *FEMS Microbiol Ecol*, 2014, **90**, 264–  
 275.

- 791 35 L. L. Kinkel, World Intellectual Property Organization, 851  
792 WO2020023808A1, 2020. 852
- 793 36 S. P. Diggle, A. Gardner, S. A. West and A. S. Griffin, *Philos Trans R Soc Lond B Biol Sci*, 2007, **362**, 1241–1249. 853
- 794 37 K. Winzer, K. R. Hardie and P. Williams, *Current Opinion in Microbiology*, 2002, **5**, 216–222. 854
- 795 38 G. Yim, H. H. Wang and J. Davies, *Philosophical Transactions: Biological Sciences*, 2007, **362**, 1195–1200. 855
- 796 39 P. V. Jauri, M. G. Bakker, C. E. Salomon and L. L. Kinkel, *PLOS ONE*, 2013, **8**, e81064. 856
- 797 40 W. C. Ratcliff and R. F. Denison, *Science*, 2011, **332**, 547–548. 857
- 798 41 D. Maura, R. Hazan, T. Kitao, A. E. Ballok and L. G. Rahme, *Scientific Reports*, 2016, **6**, 34083. 858
- 799 42 M. Kostylev, D. Y. Kim, N. E. Smalley, I. Salukhe, E. P. Greenberg and A. A. Dandekar, *Proc Natl Acad Sci USA*, 2019, **116**, 7027–7032. 859
- 800 43 A. O. Brachmann, S. Brameyer, D. Kresovic, I. Hitkova, Y. Kopp, C. Manske, K. Schubert, H. B. Bode and R. Heermann, *Nature Chemical Biology*, 2013, **9**, 573–578. 860
- 801 44 R. Hassan, M. I. Shaaban, F. M. Abdel Bar, A. M. El-Mahdy and S. Shokralla, *Frontiers in Microbiology*, 2016, **7**, 1–12. 861
- 802 45 C. Grandclément, M. Tannières, S. Moréra, Y. Dessaux and D. Faure, *FEMS Microbiology Reviews*, 2016, **40**, 86–116. 862
- 803 46 Y. Dessaux and D. Faure, *Genes*, 2018, **9**, 210. 863
- 804 47 M. Rodríguez, M. Torres, L. Blanco, V. Béjar, I. Sampedro and L. Llamas, *Scientific Reports*, 2020, **10**, 4121. 864
- 805 48 I. Joint, K. Tait and G. Wheeler, *Philosophical Transactions of the Royal Society B: Biological Sciences*, 2007, **362**, 1223–1233. 865
- 806 49 U. von Rad, I. Klein, P. I. Dobrev, J. Kottova, E. Zazimalova, A. Fekete, A. Hartmann, P. Schmitt-Kopplin and J. Durner, *Planta*, 2008, **229**, 73–85. 866
- 807 50 E. F. Vesty, A. L. Whitbread, S. Needs, W. Tanko, K. Jones, N. Halliday, F. Ghaderiadekani, X. Liu, M. Cámara and J. C. Coates, *Scientific Reports*, 2020, **10**, 2614. 867
- 808 51 J. F. González, M. P. Myers and V. Venturi, *Molecular Plant Pathology*, 2013, **14**, 211–221. 868
- 809 52 S. E. Jones and M. A. Elliot, *Trends in Microbiology*, 2017, **25**, 522–531. 869
- 810 53 S. E. Jones, L. Ho, C. A. Rees, J. E. Hill, J. R. Nodwell and M. A. Elliot, *eLife*, 2017, **6**, 1–21. 870
- 811 54 P. G. Becher, V. Verschut, M. J. Bibb, M. J. Bush, B. P. Molnár, Barane, M. M. Al-Bassam, G. Chandra, L. Song, G. L. Challis, M. Buttner and K. Flårdh, *Nature Microbiology*, 2020, **5**, 821–829. 871
- 812 55 M. Kos, M. A. B. Tuijl, J. de Roo, P. P. J. Mulder and T. M. Bezemer, *Journal of Ecology*, 2015, **103**, 904–914. 872
- 813 56 D. V. Badri, G. Zolla, M. G. Bakker, D. K. Manter and J. M. Vivanco, *New Phytologist*, 2013, **198**, 264–273. 873
- 814 57 G. C. Song and C.-M. Ryu, *International Journal of Molecular Sciences*, 2013, **14**, 9803–9819. 874
- 815 58 K. Srirangan, X. Liu, L. Akawi, M. Bruder, M. Moo-Young and C. P. Chou, *Appl. Environ. Microbiol.*, 2016, **82**, 2574–2584. 875
- 816 59 A. K. El-Sayed, J. Hothersall and C. M. Thomas, *Microbiology-Sgm*, 2001, **147**, 2127–2139. 876
- 817 60 J. Hothersall, A. C. Murphy, Z. Iqbal, G. Campbell, E. R. Stephens, J. Wu, H. Cooper, S. Atkinson, P. Williams, J. Crosby, C. L. Willis, R. J. Cox, T. J. Simpson and C. M. Thomas, *Applied Microbiology and Biotechnology*, 2011, **90**, 1017–1026. 877
- 818 61 N.-H. Hsiao, S. Nakayama, M. E. Merlo, M. de Vries, R. Bunet, S. Kitani, T. Nihira and E. Takano, *Chemistry & Biology*, 2009, **16**, 951–960. 878
- 819 62 S. Kitani, K. T. Miyamoto, S. Takamatsu, E. Herawati, H. Iguchi, K. Nishitomi, M. Uchida, T. Nagamitsu, S. Omura, H. Ikeda and T. Nihira, *PNAS*, 2011, **108**, 16410–16415. 879
- 820 63 E. Takano, *Current Opinion in Microbiology*, 2006, **9**, 287–294. 880
- 821 64 Y. Ohnishi, S. Kameyama, H. Onaka and S. Horinouchi, *Molecular Microbiology*, 1999, **34**, 102–111. 881
- 822 65 E. Takano, R. Chakraborty, T. Nihira, Y. Yamada and M. J. Bibb, *Molecular Microbiology*, 2001, **41**, 1015–1028. 882
- 823 66 A. Tsigkinopoulou, E. Takano and R. Breitling, *PLOS Computational Biology*, 2020, **16**, e1008039. 883
- 824 67 J. P. Gomez-Escribano, L. Song, D. J. Fox, V. Yeo, M. J. Bibb and G. L. Challis, *Chem. Sci.*, 2012, **3**, 2716–2720. 884
- 825 68 Y. Zhang, M. Wang, J. Tian, J. Liu, Z. Guo, W. Tang and Y. Chen, *Applied Microbiology and Biotechnology*, 2020, **104**, 1695–1705. 885
- 826 69 E. Takano, H. Kinoshita, V. Mersinias, G. Bucca, G. Hotchkiss, T. Nihira, C. P. Smith, M. Bibb, W. Wohlleben and K. Chater, *Molecular Microbiology*, 2005, **56**, 465–479. 886
- 827 70 X. Li, J. Wang, S. Li, J. Ji, W. Wang and K. Yang, *Sci Rep*, 2015, **5**, 14831. 887
- 828 71 B. Bednarz, A. Millan-Oropeza, M. Kotowska, M. Świat, J. J. Quispe Haro, C. Henry and K. Pawlik, *Frontiers in Microbiology*, 2021, **12**, 787. 888
- 829 72 W. Wang, J. Ji, X. Li, J. Wang, S. Li, G. Pan, K. Fan and K. Yang, *PNAS*, 2014, **111**, 5688–5693. 889
- 830 73 E. P. Guthrie, C. S. Flaxman, J. White, D. A. Hodgson, M. J. Bibb and K. F. Chater, *Microbiology (Reading)*, 1998, **144 (Pt 3)**, 727–738. 890
- 831 74 V. H. T. Pham and J. Kim, *Trends in Biotechnology*, 2012, **30**, 475–484. 891
- 832 75 D. Nichols, N. Cahoon, E. M. Trakhtenberg, L. Pham, A. Mehta, A. Belanger, T. Kanigan, K. Lewis and S. S. Epstein, *Appl. Environ. Microbiol.*, 2010, **76**, 2445–2450. 892
- 833 76 L. L. Ling, T. Schneider, A. J. Peoples, A. L. Spoering, I. Engels, B. P. Conlon, A. Mueller, D. E. Hughes, S. Epstein, M. Jones, L. Lazarides, V. A. Steadman, D. R. Cohen, C. R. Felix, K. A. Fetterman, W. P. Millett, A. G. Nitti, A. M. Zullo, C. Chen and K. Lewis, *Nature*, 2015, **517**, 455–459. 893
- 834 77 E. Gonzalez, F. E. Pitre, A. P. Pagé, J. Marleau, W. Guidi Nissim, M. St-Arnaud, M. Labrecque, S. Joly, E. Yergeau and N. J. B. Brereton, *Microbiome*, 2018, **6**, 53. 894
- 835 78 E. Yergeau, J. Tremblay, S. Joly, M. Labrecque, C. Maynard, F. E. Pitre, M. St-Arnaud and C. W. Greer, *The ISME Journal*, 2018, **12**, 869–884. 895
- 836 79 Q. Bei, G. Moser, X. Wu, C. Müller and W. Liesack, *Soil Biology and Biochemistry*, 2019, **138**, 107604. 896
- 837 80 S. A. Amin, L. R. Hmelo, H. M. van Tol, B. P. Durham, L. T. Carlson, K. R. Heal, R. L. Morales, C. T. Berthiaume, M. S. Parker, B. Djunaedi, A. E. Ingalls, M. R. Parsek, M. A. Moran and E. V. Armbrust, *Nature*, 2015, **522**, 98–101. 897
- 838 81 M. R. Seyedsayamdost, *PNAS*, 2014, **111**, 7266–7271. 898
- 839 82 T. Nobori, A. C. Velásquez, J. Wu, B. H. Kvitko, J. M. Kremer, Y. Wang, S. Y. He and K. Tsuda, *PNAS*, 2018, **115**, E3055–E3064. 899
- 840 83 M. Kumar, B. Ji, K. Zengler and J. Nielsen, *Nature Microbiology*, 2019, **4**, 1253–1267. 900
- 841 84 W. R. Harcombe, W. J. Riehl, I. Dukovski, B. R. Granger, A. Betts, A. H. Lang, G. Bonilla, A. Kar, N. Leiby, P. Mehta, C. J. Marx and D. Segrè, *Cell Rep*, 2014, **7**, 1104–1115. 901
- 842 85 J. Nelkner, C. Henke, T. W. Lin, W. Pätzold, J. Hassa, S. Jaenicke, R. Grosch, A. Pühler, A. Sczyrba and A. Schlüter, *Genes*, 2019, **10**, 424. 902
- 843 86 Z.-B. Zhao, J.-Z. He, Z. Quan, C.-F. Wu, R. Sheng, L.-M. Zhang and S. Geisen, *Soil Biology and Biochemistry*, 2020, **148**, 107863. 903

Review

Natural Product Reports

87 W. Wang, Z. Wang, K. Yang, P. Wang, H. Wang, L. Guo, S. Zhu, 973  
 914 Zhu and X. He, *Front. Microbiol.*, 2020, **11**, 799. 974

88 Y. Wang, M. Li, C. Jiang, M. Liu, M. Wu, P. Liu, Z. Li, M. Uchimiya, 975  
 916 and X. Yuan, *Science of The Total Environment*, 2020, **726**, 976  
 917 138562. 977

89 J. P. Dundore-Arias, S. C. Castle, L. Felice, R. Dill-Macky and L. 978  
 919 Kinkel, *Front. Mol. Biosci.*, 2020, **6**, 151. 979

90 J. P. Dundore-Arias, L. Felice, R. Dill-Macky and L. L. Kinkel, 980  
 921 *Front. Microbiol.*, 2019, **10**, 498. 981

91 M. Schwab, C. Bergonzi, J. Sakkos, C. Staley, Q. Zhang, M. J. 982  
 923 Sadowsky, A. Aksan and M. Elias, *Front. Microbiol.*, 2019, **10**, 983  
 924 611. 984

92 H. Li, X. Ding, C. Chen, X. Zheng, H. Han, C. Li, J. Gong, T. Xu, Q. 985  
 926 Li, G. Ding and J. Li, *FEMS Microbiol Ecol*, 2019, **95**, fiz023. 986

93 T. Whitfill and J. Oh, *Current Opinion in Microbiology*, 2019, **50**, 987  
 928 28–34. 988

94 C. Ronda, S. P. Chen, V. Cabral, S. J. Yaung and H. H. Wang, 989  
 930 *Nature Methods*, 2019, **16**, 167–170. 990

95 X.-T. Fan, H. Li, Q.-L. Chen, Y.-S. Zhang, J. Ye, Y.-G. Zhu and J.-Q. 991  
 932 Su, *Front. Microbiol.*, 2019, **10**, 194. 992

96 M. Stritzler, G. Soto and N. Ayub, *Microb Ecol*, 2018, **76**, 579– 993  
 934 583. 994

97 Z. Heydarian, M. Yu, M. Gruber, B. R. Glick, R. Zhou and D. D. 995  
 936 Hegedus, *Front. Microbiol.*, 2016, **7**, 1966. 996

98 M. Rafique, T. Sultan, I. Ortas and H. J. Chaudhary, *Soil Science* 997  
 938 *and Plant Nutrition*, 2017, **63**, 460–469. 998

99 L. Riahi, H. Cherif, S. Miladi, M. Neifar, B. Bejaoui, H. Chouchane, 999  
 940 A. S. Masmoudi and A. Cherif, *Industrial Crops and Products*, 1000  
 941 2020, **154**, 112721. 1001

100 K. Tamreihao, D. S. Ningthoujam, S. Nimaichand, E. S. Singh, R. 1002  
 942 Reena, S. H. Singh and U. Nongthomba, *Microbiological* 1003  
 943 *Research*, 2016, **192**, 260–270. 1004

101 D. Nassal, M. Spohn, N. Eltlbany, S. Jacquioid, K. Smalla, S. 1005  
 944 Marhan and E. Kandeler, *Plant Soil*, 2018, **427**, 17–37. 1006

102 J. I. Rilling, J. J. Acuña, P. Nannipieri, F. Cassan, F. Maruyama and 1007  
 945 M. A. Jorquera, *Soil Biology and Biochemistry*, 2019, **130**, 2054–1008  
 946 219. 1009

103 D. T. Riglar, T. W. Giessen, M. Baym, S. J. Kerns, M. J. 1010  
 947 Niederhuber, R. T. Bronson, J. W. Kotula, G. K. Gerber, J. C. Wainwright 1011  
 948 and P. A. Silver, *Nature Biotechnology*, 2017, **35**, 653–658. 1012

104 A. S. Devlin, A. Marcobal, D. Dodd, S. Nayfach, N. Plummer, T. 1013  
 949 Meyer, K. S. Pollard, J. L. Sonnenburg and M. A. Fischbach, *Cell* 1014  
 950 *Host & Microbe*, 2016, **20**, 709–715. 1015

105 G. R. Kudoyarova, L. B. Vysotskaya, T. N. Arkhipova, L. Yu. 1016  
 951 Kuzmina, N. F. Galimsyanova, L. V. Sidorova, I. M. Gabbasova, I. 1017  
 952 Melentiev and S. Yu. Veselov, *Acta Physiol Plant*, 2017, **39**, 1018  
 953 253. 1019

106 N. Pongsilp and P. Nimnoi, *Scientific Reports*, 2020, **10**, 15857–1020  
 954 7020. 1021

107 W. Ju, X. Jin, L. Liu, G. Shen, W. Zhao, C. Duan and L. Fang, 1022  
 955 *Applied Soil Ecology*, 2020, **150**, 103450. 1022

108 J. Hu, Z. Wei, V.-P. Friman, S. Gu, X. Wang, N. Eisenhauer, T. 1023  
 956 Yang, J. Ma, Q. Shen, Y. Xu and A. Jousset, *mBio*, 2016, **7**, 1024  
 957 e01790-16. 1025

109 E. R. J. Wubs, W. H. van der Putten, M. Bosch and T. M. 1026  
 958 Bezemer, *Nature Plants*, 2016, **2**, 1–5. 1027

110 E. D. Lee, E. R. Aurand, D. C. Friedman, and Engineering Biology 1028  
 959 Research Consortium Microbiomes Roadmapping Working 1029  
 960 Group, *ACS Synth. Biol.*, 2020, **9**, 3181–3183. 1030

111 Q. Guo, M. Shi, L. Chen, J. Zhou, L. Zhang, Y. Li, Q. Xue and H. 1031  
 961 Lai, *Soil Biology and Biochemistry*, 2020, **144**, 107755. 1032  
 962 1033  
 1034

112 A. Essarioui, N. LeBlanc, L. Otto-Hanson, D. C. Schlatter, H. C. 1035  
 963 Kistler and L. L. Kinkel, *Environmental Microbiology*, 2020, **22**, 1036  
 964 976–985. 1037

113 O. M. Finkel, I. Salas-González, G. Castrillo, J. M. Conway, T. F. 1038  
 965 Law, P. J. P. L. Teixeira, E. D. Wilson, C. R. Fitzpatrick, C. D. Jones 1039  
 966 and J. L. Dangl, *Nature*, 2020, **587**, 103–108. 1040

114 M. Simonin, C. Dasilva, V. Terzi, E. L. M. Ngonkeu, D. Diouf, A. 1041  
 967 Kane, G. Béna and L. Moulin, *FEMS Microbiol Ecol*, 2020, **96**, 1042  
 968 fiae067. 1043

115 W. Tan, J. Wang, W. Bai, J. Qi and W. Chen, *Scientific Reports*, 1044  
 969 2020, **10**, 6012. 1045

116 W. A. Walters, Z. Jin, N. Youngblut, J. G. Wallace, J. Sutter, W. 1046  
 970 Zhang, A. González-Peña, J. Peiffer, O. Koren, Q. Shi, R. Knight, T. 1047  
 971 G. del Rio, S. G. Tringe, E. S. Buckler, J. L. Dangl and R. E. Ley, 1048  
 972 *PNAS*, 2018, **115**, 7368–7373. 1049

117 Y. Tong, C. M. Whitford, K. Blin, T. S. Jørgensen, T. Weber and S. 1050  
 973 Y. Lee, *Nature Protocols*, 2020, **15**, 2470–2502. 1051

118 Y. Tong, C. M. Whitford, H. L. Robertsen, K. Blin, T. S. Jørgensen, 1052  
 974 A. K. Klitgaard, T. Gren, X. Jiang, T. Weber and S. Y. Lee, *PNAS*, 1053  
 975 2019, **116**, 20366–20375. 1054

119 Y. Zhao, L. Li, G. Zheng, W. Jiang, Z. Deng, Z. Wang and Y. Lu, 1055  
 976 *Biotechnology Journal*, 2018, **13**, 1800121. 1056

120 S. Ye, B. Enghiad, H. Zhao and E. Takano, *J Ind Microbiol* 1057  
 977 *Biotechnol*, 2020, **47**, 413–423. 1058

121 Y. Tong, P. Charusanti, L. Zhang, T. Weber and S. Y. Lee, *ACS* 1059  
 978 *Synth Biol*, 2015, **4**, 1020–1029. 1060

122 H. Huang, G. Zheng, W. Jiang, H. Hu and Y. Lu, *Acta Biochim* 1061  
 979 *Biophys Sin (Shanghai)*, 2015, **47**, 231–243. 1062

123 R. E. Cobb, Y. Wang and H. Zhao, *ACS synthetic biology*, 2015, **4**, 1063  
 980 723–8. 1064

124 F. Alberti and C. Corre, *Nat. Prod. Rep.*, 2019, **36**, 1237–1248. 1065

125 D. G. Gibson, L. Young, R.-Y. Chuang, J. C. Venter, C. A. 1066  
 981 Hutchison and H. O. Smith, *Nature Methods*, 2009, **6**, 343–345. 1067

126 C. Engler, R. Kandzia and S. Marillonnet, *PLOS ONE*, 2008, **3**, 1068  
 982 e3647. 1069

127 C. D. Smolke, *Nature Biotechnology*, 2009, **27**, 1099–1102. 1070

128 C. J. McClune, A. Alvarez-Buylla, C. A. Voigt and M. T. Laub, 1071  
 983 *Nature*, 2019, **574**, 702–706. 1072

129 M. Biarnes-Carrera, C. K. Lee, T. Nihira, R. Breitling and E. 1073  
 984 Takano, *ACS Synthetic Biology*, 2018, **7**, 1043–1055. 1074

130 P. Jacquet, J. Hiblot, D. Daudé, C. Bergonzi, G. Gotthard, N. 1075  
 985 Armstrong, E. Chabrière and M. Elias, *Scientific Reports*, 2017, **7**, 1076  
 986 16745. 1077

131 X. Liu, L. Cao, X. Fan, Y. Liu and W. Xie, *Scientific Reports*, 2016, 1078  
 987 **6**, 38137. 1079

132 J. Y. Chow, L. Wu and W. S. Yew, *Biochemistry*, 2009, **48**, 4344– 1080  
 988 4353. 1081

133 W. Kong, D. R. Meldgin, J. J. Collins and T. Lu, *Nature Chemical* 1082  
 989 *Biology*, 2018, **14**, 821–829. 1083

134 H. Honjo, K. Iwasaki, Y. Soma, K. Tsuruno, H. Hamada and T. 1084  
 990 Hanai, *Metabolic Engineering*, 2019, **55**, 268–275. 1085

135 B. A. Geddes, P. Paramasivan, A. Joffrin, A. L. Thompson, K. 1086  
 991 Christensen, B. Jorrin, P. Brett, S. J. Conway, G. E. D. Oldroyd and 1087  
 992 P. S. Poole, *Nature Communications*, 2019, **10**, 1–11. 1088

136 N. Saeidi, C. K. Wong, T.-M. Lo, H. X. Nguyen, H. Ling, S. S. J. 1089  
 993 Leong, C. L. Poh and M. W. Chang, *Molecular Systems Biology*, 1090  
 994 2011, **7**, 521. 1091

137 S. E. Bloch, R. Clark, S. S. Gottlieb, L. K. Wood, N. Shah, S.-M. 1092  
 995 Mak, J. G. Lorigan, J. Johnson, A. G. Davis-Richardson, L. 1093  
 996 Williams, M. McKellar, D. Soriano, M. Petersen, A. Horton, O. 1094  
 997 Smith, L. Wu, E. Tung, R. Broglie, A. Tamsir and K. Temme, 1095  
 998 *Journal of Experimental Botany*, 2020, **71**, 4591–4603. 1096

## Natural Product Reports

## Review

- 1035 138 M.-H. Ryu, J. Zhang, T. Toth, D. Khokhani, B. A. Geddes, F. Mus,  
1036 A. Garcia-Costas, J. W. Peters, P. S. Poole, J.-M. Ané and C. A.  
1037 Voigt, *Nature Microbiology*, 2020, **5**, 314–330.
- 1038 139 K. Stephens, M. Pozo, C.-Y. Tsao, P. Hauk and W. E. Bentley,  
1039 *Nature Communications*, 2019, **10**, 1–11.
- 1040 140 C. Virgile, P. Hauk, H.-C. Wu, W. Shang, C.-Y. Tsao, G. F. Payne  
1041 and W. E. Bentley, *PLOS ONE*, 2018, **13**, e0196999.
- 1042 141 K. Panke-Buisse, A. C. Poole, J. K. Goodrich, R. E. Ley and J. Kao-  
1043 Kniffin, *The ISME Journal*, 2015, **9**, 980–989.
- 1044 142 M. D. Jochum, K. L. McWilliams, E. A. Pierson and Y.-K. Jo, *PLOS*  
1045 *ONE*, 2019, **14**, e0225933.
- 1046 143 U. G. Mueller, T. E. Juenger, M. R. Kardish, A. L. Carlson, K.  
1047 Burns, J. A. Edwards, C. C. Smith, C.-C. Fang and D. L. D. Marais,  
1048 *bioRxiv*, 2019, Preprint, 10.1101/081521.
- 1049 144 Z. Wei, Y. Gu, V.-P. Friman, G. A. Kowalchuk, Y. Xu, Q. Shen and  
1050 A. Jousset, *Sci. Adv.*, 2019, **5**, eaaw0759.
- 1051 145 L. Xie, A. E. Yuan and W. Shou, *PLOS Biology*, 2019, **17**,  
1052 e3000295.  
1053  
1054